ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 99.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,150 shares of the biopharmaceutical company's stock after selling 2,465,581 shares during the period. SG Americas Securities LLC's holdings in ACADIA Pharmaceuticals were worth $301,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Principal Financial Group Inc. grew its stake in ACADIA Pharmaceuticals by 10.9% during the 4th quarter. Principal Financial Group Inc. now owns 143,694 shares of the biopharmaceutical company's stock worth $2,637,000 after purchasing an additional 14,143 shares in the last quarter. New York State Common Retirement Fund boosted its stake in shares of ACADIA Pharmaceuticals by 14.0% in the 4th quarter. New York State Common Retirement Fund now owns 51,374 shares of the biopharmaceutical company's stock valued at $943,000 after buying an additional 6,310 shares during the period. Handelsbanken Fonder AB grew its position in shares of ACADIA Pharmaceuticals by 15.1% during the fourth quarter. Handelsbanken Fonder AB now owns 54,833 shares of the biopharmaceutical company's stock worth $1,006,000 after buying an additional 7,200 shares in the last quarter. Los Angeles Capital Management LLC grew its position in shares of ACADIA Pharmaceuticals by 158.6% during the fourth quarter. Los Angeles Capital Management LLC now owns 114,535 shares of the biopharmaceutical company's stock worth $2,102,000 after buying an additional 70,238 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter worth approximately $272,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ACAD. Royal Bank Of Canada lifted their price target on shares of ACADIA Pharmaceuticals from $26.00 to $38.00 and gave the stock an "outperform" rating in a research note on Monday, June 23rd. UBS Group decreased their price objective on shares of ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a research report on Monday, April 28th. Deutsche Bank Aktiengesellschaft upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating and boosted their target price for the stock from $20.00 to $35.00 in a research note on Wednesday, May 21st. Robert W. Baird raised their price target on ACADIA Pharmaceuticals from $28.00 to $31.00 and gave the company an "outperform" rating in a research note on Monday, May 19th. Finally, JPMorgan Chase & Co. lifted their price target on ACADIA Pharmaceuticals from $26.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, June 6th. Six equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $27.88.

ACADIA Pharmaceuticals Stock Down 2.5%

NASDAQ:ACAD traded down $0.55 during mid-day trading on Monday, reaching $21.57. 1,626,794 shares of the stock were exchanged, compared to its average volume of 1,961,032. The stock has a market capitalization of $3.61 billion, a P/E ratio of 15.74, a P/E/G ratio of 4.77 and a beta of 0.64. ACADIA Pharmaceuticals Inc. has a 1 year low of $13.40 and a 1 year high of $25.23. The company has a 50 day simple moving average of $19.74 and a 200-day simple moving average of $18.26.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. ACADIA Pharmaceuticals had a net margin of 22.97% and a return on equity of 17.46%. The business had revenue of $244.32 million for the quarter, compared to analyst estimates of $239.32 million. During the same period last year, the firm posted $0.10 earnings per share. The company's revenue for the quarter was up 18.7% compared to the same quarter last year. As a group, research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, Director Laura Brege sold 14,446 shares of the company's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $21.78, for a total transaction of $314,633.88. Following the completion of the sale, the director directly owned 15,095 shares of the company's stock, valued at $328,769.10. This represents a 48.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James Kihara sold 4,000 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $22.50, for a total value of $90,000.00. Following the sale, the insider directly owned 20,395 shares of the company's stock, valued at approximately $458,887.50. This represents a 16.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,007 shares of company stock worth $580,446. 28.30% of the stock is owned by company insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.